Group items matching

in title, tags, annotations or url

The Criminal Enforcement Unit (CEU) of the Medicines and Healthcare products Regulatory Agency (MHRA) seized a large quantity of suspected illegally traded Medicines, including powerful prescription-only Medicines, during raids conducted at two residential and two business premises across North Manchester. Officers from the MHRA and Greater Manchester Police carried out searches across two residential addresses in Oldham and Cheetham in the early hours of Wednesday (29 November), and arrested a man in his 20s on "suspicion of conspiracy to supply controlled drugs, breaches of the Human Medicines Regulations 2012 and money laundering." They also seized thousands of illegal Medicines from two business addresses in Bury and Miles Platting, including powerful opioid painkillers and antidepressants, as well as unlicensed versions of erectile dysfunction drugs.

The European Commission is prepared to rewrite European Union law on medicines to ensure stable supply of generic and life-saving medicines in Northern Ireland. In a press statement issued on Friday (Dec 17), the commission said it put forward a package of measures to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland. In the context of the Northern Ireland Protocol, this means that the same medicines will continue to be available at the same time across the United Kingdom. Commenting on the news, policy manager at the National Pharmacy Association (NPA) Helga Mangion said: "We are encouraged by the EU's statement on medicines availability in Northern Ireland, though of course we await the final outcome of the negotiations. We have been talking to the government, the MHRA and other stakeholders about these issues for months, highlighting the concerns of our members in Northern Ireland."

The Royal Pharmaceutical Society (RPS) has backed a new framework from NHS England to reduce inappropriate prescribing of addiction-causing medicines. It believes that the new framework is a positive step towards improving patient care by supporting medicine reviews and shared decision making to help people reduce their use of medicines that are no longer providing much clinical benefit. The society has also welcomed investment in innovative approaches to supporting patients and urged all pharmacists to refer people to such schemes. Director for England at RPS, James Davies said: "Pharmacists are well-placed to help reduce inappropriate prescribing of high strength painkillers such as opioids and other addictive medicines. "Pharmacy teams can also often spot repeat purchases of over the counter medicines by patients so are well placed to intervene and give advice on the management of chronic pain. Whilst opioids can play an important part in helping people with chronic pain there has long been a need for alternative approaches that are safer and more effective for patients.

A report released by Community Pharmacy England (CPE) has warned that pharmacies across England are grappling with daily medicine supply challenges, posing significant risks to patients' health. The Pharmacy Pressures Survey 2024: medicines Supply Report, which is based on the views of the owners of over 6,100 pharmacy premises in England and 2,000 pharmacy team members, has exposed some alarming trends concerning medicine supply problems in the country. Almost all pharmacy team members surveyed (97 per cent) reported patients being inconvenienced due to medicine supply issues, and 79 per cent of the participants said that the worsening situation is putting patient health at risk. Nearly all respondents reported patient frustration stemming from medicine supply issues, with 84 per cent of them saying they had experienced aggression from patients. Additionally, 98 per cent indicated an increase in 'owings,' where patients receive only part of their prescription and must return to the pharmacy for the remaining medication(s) at a later time."

PRODUCT DESCRIPTION SANDHI SUDHA PLUS OIL IN PAKISTAN What is Sandhi Sudha Plus Oil ? Sandhi Sudha Plus Oil, is an Ayurvedic product made from Hamaliyan. It contains rare & precious plants extracts which are found in the Himalayas. It has been used for decades by millions of people and has produced magical result. It helps pain of knees, body, back, shoulder pain etc in 10 to 15 days of use. By using this, the joints in the body become stronger and by using it for 10 to 15 days it helps to re build the lost Synovial Fluid between the joints. It brings proper and normal movement back in the joints and in all of body.You can use the Sandhi Sudha Plus joint Pain Relief Oil two hours before taking shower/bathing, or two hours after it, or even before you sleep at night. For the maximum benefit, give hot fomentation after massaging the affected area. MOST EFFECTIVE ON:OPENTELESHOP ➤knee pain ➤shoulder pains ➤back pain ➤cervical spondilitis ➤arthritis *This oil shows magical results for women with back pain. HOW TO USE SANDHI SUDHA PLUS OIL:OPENTELESHOP? Sandhi Sudha Plus Is For External Application Only. Take One Or Two Teaspoons (Approximately 5 Ml) Of The Oil In A Bowl Or In Your Palm. Dip Your Fingertips In The Oil And Start Massaging The Affected Area Gently With Fingertips. Make Sure That The Pressure Is Not Too Much While Applying And The Area Of Application Is Clean And Without Any Cuts Or Wounds. Keep The Motion Circular In Direction And Keep Massaging For 3-5 Minutes. The Application Should Be Repeated 3-4 Times In A Day For 15 Days And Further As And When Need Be. For The Maximum Benefit, Give Hot Fomentation After Massaging The Affected Area. BENEFITS OF SANDHI SUDHA PLUS OIL:OPENTELESHOP Sandhi Sudha Plus is an advanced product which besides reducing the pain in joints also reduces the swallowing & stiffness in the joints. The joints in your body become stronger and the oil bring back the lost Synovial Fluid between the joints as a result of

The Medicines and Healthcare Products Regulatory Agency (MHRA) is considering the reclassification of Aquiette 2.5mg tablets contains oxybutynin hydrochloride that is used to treat women with milder symptoms of overactive bladder from Prescription-Only-Medicine (POM) to Pharmacy (P) Medicine. The agency is encouraging pharmacists, GPs and other health care professionals, the public and women to take part in the reclassification consultation to make a treatment for overactive bladder available for women without the need for a prescription. Public consultation on a set of proposals to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies will close on 13 May, 2022. It would be the first time a Medicine for the treatment of overactive bladder would be available without prescription, if the reclassification consultation receives positive responses. After the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this Medicine safely.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on the reclassification of codeine linctus to a prescription-only Medicine after considering multiple Yellow Card reports for its opioid effects, rather than for its intended use as a cough suppressant. This medication is currently licensed as a pharmacy Medicine, which means that it is available to purchase over the counter in pharmacies. If reclassified as a prescription-only Medicine, all strengths of codeine linctus will only be available upon presentation of a prescription. Dr Alison Cave, MHRA Chief Safety Officer, said: "Codeine linctus is an effective Medicine, but as it is an opioid, its misuse and abuse can have major health consequences. Every response received will help us to develop a broader view on whether codeine linctus should be restricted to prescription-only status. We want to hear from members of the public, health professionals and others who would be affected by this potential change so we can make a properly considered decision for the benefit of patients, carers, and healthcare professionals across the UK.

Proposed changes to a European Union pharmaceuticals law will include stronger obligations for the supply of medicines and earlier notifications of shortages, EU Health Commissioner Stella Kyriakides said last week (January 17). Kyriakides told a session of the European Parliament that shortages of antibiotics are a growing problem for many European countries. She said the European Commission's proposal to revise the pharmaceuticals legislation is planned for March. "Our objective is and remains to secure access to medicines for all patients in need and to avoid any market disruption of medicines in the EU," Kyriakides said. Shortages of antibiotics have been reported in 26 European countries, the European medicines Agency says. The unseasonably early upsurge in respiratory infections in Europe this winter and insufficient production capacity are the root causes of the shortages, Kyriakides said. Numerous EU lawmakers speaking at the session said the shortages needed to be tackled urgently. But experts say shortages of essential generic medicines like antibiotics are likely to be recurrent in Europe due to problems in the sector such as the gradual migration of generic manufacturing to Asia.

Three leading healthcare bodies in Scotland have called for action to reduce the environmental impact caused by medicine prescribing. The Academy of Medical Royal Colleges and Faculties in Scotland, Royal Pharmaceutical Society and the Royal College of General Practitioners Scotland have all urged policymakers to enable a more sustainable approach to prescribing. This includes prioritising the introduction of electronic prescribing across the NHS, introducing the requirement for an environmental impact in NHS medicines procurement and improving the availability of data about the environmental impact of medicines. "We call on Scottish government, including the chief medical officer, to enable the delivery of a realistic medicine approach to prescribing by developing a supportive infrastructure for green social prescribing across Scotland," said the healthcare professionals in a joint statement. They have called on the pharmaceutical industry to make information about the environmental impact of medicines readily available in a standardised data format.

The National Pharmacy Association (NPA) has asked the Secretary of State for Health and Social Care to convene a 'medicines supply taskforce', following weeks of problems with antibiotics supplies. The NPA's chief executive Mark Lyonette wrote a letter to Steve Barclay this week. It cited the precedent of the HRT Taskforce which this summer brought together representatives from across the supply chain after months of supply problems affecting women. "We strongly believe that this situation calls for a similar response from the government. It is imperative that we resolve this supply situation urgently and therefore we request that you convene a medicines Supply Taskforce, with all the relevant stakeholders in the supply chain, to urgently discuss and agree practical solutions to address the disruptions to the supply of medicines. HRT and antibiotics are the most visible examples of a wider problem with medicines supply which needs to be addressed." NPA board members Olivier Picard and Reena Barai were among the stakeholders joining meetings convened by the HRT Taskforce this summer.

Rilutek 50Mg Tablet Indian Suppliers , This medication is employed to treat an explicit form of nerve unwellness known as amyotrophic lateral pathology (ALS, conjointly normally known as Lou Gehrig's disease). Riluzole helps to bog down the worsening of this unwellness and prolong survival. However, it's not a cure for ALS, and it doesn't reverse nerve injury or muscle weakness. We are leading suppliers & exporters of "Rilutek 50Mg" in China, Russia, Hongkong, Bulgaria, Romania, India.We're largest suppliers of Aventis medicines & provide you the best price on Rilutek 50Mg. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Rilutek 50Mg Tablet Indian Suppliers Rilutek 50Mg Suppliers India Rilutek 50Mg Riluzole is believed to figure by protective the nerves within the brain and neural structure from an excessive amount of a natural substance known as salt which will be a part of the reason behind nerve injury. RILUTEK (riluzole) may be a member of the benzothiazole category. The chemical designation for riluzole is 2-amino-6-(trifluoromethoxy) benzothiazole. Its chemical formula is C8H5F3N2OS, and its relative molecular mass is 234.2. RILUTEK may be a white to slightly yellow powder that's terribly soluble in dimethylformamide, dimethylsulfoxide, and methanol; freely soluble in dichloromethane; meagrely soluble in zero.1 N HCl; and extremely slightly soluble in water and in zero.1 N NaOH. Each film-coated Tablet for oral use contains 50 mg of riluzole and also the following inactive ingredients: anhydrous dibasic inorganic phosphate, mixture silica, croscarmellose atomic number 11, hypromellose, Mg stearate, crystalline polysaccharide, synthetic resin glycol, and titanium oxide. If you're mistreatment the liquid type of this medication, gently shake the bottle for a minimum of thirty seconds before use. Rigorously live the dose employing a special mensuration device/spoon. Don't use a

Pharmacist supervision has been the subject of debate for as long as I can remember. Strikingly, no one is sure what supervision requires. The Human Medicines Regulations 2012 say it is a criminal offence to sell or supply Pharmacy Medicines or Prescription Only Medicines unless a pharmacist makes the sale or supply or, if the transaction is carried out by a non-pharmacist, that person acts under the supervision of a pharmacist. Over the years, some people have argued that supervision requires a clinical check. Others say it requires an accuracy assessment. Yet others have asserted that it requires a final check before a Medicine leaves the pharmacy. Things are made more uncertain by the NHS terms of service which require prescription Medicines to be supplied under the direct supervision of a pharmacist. No one knows what the word "direct" adds. The wording of the Human Medicines Regulations is not identical to the wording of earlier legislation. In particular, on the only occasions when the courts have been called upon to interpret the requirement for supervision, the Pharmacy and Poisons Act 1933 was in force. In cases decided in 1943 and 1953, the courts decided that a pharmacist who was upstairs when a supply was made could not have been supervising; and that a sale was supervised by pharmacist standing at the cash desk because the pharmacist could intervene if a sale would not be appropriate.

Storing your medication properly is important. Only if they have their place in the house will you and your family members always know where to find their supplements, pain relief medications, and others. In this article, we'll try to give you some guidelines on how to manage your medication and develop a system that will work well for you and your family. Also, since medicine safety is so important, we'll share some simple tips on making sure all medications are good and when is the right time to toss them. 1. USE A BOX 2. KEEP YOUR MEDICATION IN A COLD AND DRY PLACE 3. COLOR CODE YOUR MEDICATION 4. DISPOSE OF medicine 5. ORGANIZE YOUR medicine ON THE GO 6. KEEP IT NEAT Once you find a place where medicine won't experience extreme temperatures, humidity, and strong sunlight, get a nice set of boxes and take one afternoon to make it neat and organized. Even if you're taking specific medication, ask your pharmacist what's the best place to store them. Sometimes, it might turn out that it's your fridge, but a kitchen might also be a good place to start thinking about.

The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological Medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer Medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological Medicines dominate the Medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".

The Medicines and Healthcare products Regulatory Agency's (MHRA) Criminal Enforcement Unit (CEU) has seized a quantity of suspected unlicensed medical products including unlicensed versions of Botox, numbing agents and dermal fillers in Bolton, Greater Manchester. Officers from the MHRA and Greater Manchester Police conducted a raid across nine addresses in Bolton, Westhoughton and Leigh in the early hours of Thursday 13 July 2023, where two women and a man were arrested. Andy Morling, MHRA Deputy Director of Criminal Enforcement said: "Medicines like these are powerful and dangerous in the wrong hands, potentially leading to serious adverse health consequences. The criminals trading in these products are not only breaking the law, they also have no regard for your safety. It is illegal to advertise, sell or supply Medicines such as these without the appropriate authorisation. If you see these products, or any other powerful Medicines, being sold on social media or elsewhere online, think. It's unlikely to be legitimate. You can help the MHRA take action by reporting concerns to us through our Yellow Card scheme.

The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations. A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023. Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway. "We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."

The Manchester Crown Court on Friday (9 December) sentenced three men, Cleave Lewis (35) and brothers, Denis Sutherland (58) and David Sutherland (59), to a total of three years in jail after they pleaded guilty to the illegal sale and supply online of prescription-only medicines and controlled Class B and Class C drugs, worth more than £1.5m. They were found in possession of nearly 1.3m tablets of prescription-only drugs, including powerful sleeping pills, painkillers and anti-anxiety meds, when officers from the medicines and Healthcare products Regulatory Agency (MHRA) and Greater Manchester Police searched their residential homes and business premises in October 2017. Following investigations by the agency, they also pleaded guilty to illegally making these medicines available online on three different websites for the public to purchase without prescriptions. The officials also recovered controlled medicines, over half a million (525,737) erectile dysfunction, slimming and herbal tablets, with an estimated value of approximately £500k, from them.

After I have finished playing some casino games, using my, Juicy Stakes Casino bonuses, I am hungry. What should I eat? A juicy steak (wink, wink)? Fried chicken? An Ingestible Pill? Wait, what? What is an ingestible pill? Is that a food or vitamin? Actually, it is neither. It is new technology developed by Pfizer. Pfizer is the pharmaceutical company that gave us the COVID vaccines that do not provide lifetime immunity to COVID or even prevent you from getting it in the short term. Pfizer is also the company that created the COVID medicine Paxlovid, which cause Biden to get a rebound COVID right after he supposedly recovered from COVID. Ingestible Pills are a version of a digital pill A digital pill is also known as a smart pill or an ingestible sensor. It is a pharmaceutical dosage form that contains an ingestible sensor inside of a pill. The sensor begins transmitting medical data after it is consumed. This pill and its other related technology are considered Digital medicine. The purpose of the sensor is to determine if a person is taking their medicine or they are not taking their medicine. In other words, is the patient complying with taking their medicine or are they not complying with taking their medicine?

We cannot deny the benefits and uses of regenerative medicines as they have been so in demand in recent times. One such effective medicine with a lot of potential health benefits is BPS-157. The peptide is thought to be extremely beneficial for those struggling with various neurological or health issues. Another medicine with the same beneficial effects is the Semax peptide. Well, the benefits of both these peptide-based medicines and their other aspects will be discussed in detail in this blog along with answering your question about the BPC-157 buy, Semax effects, and polypeptide. ALL ABOUT BPC-157: BPC-157, a pentadecapeptide consisting of 15 amino acids, is a synthetic peptide that is known for its positive effects on the human body. The peptide is derived from human gastric juice. A protein is present in the human gastric juice through which this peptide is derived and synthesized. It is called a Body Protection Protein as it exerts several therapeutic effects on the human body. Not only have health benefits or therapeutic effects, the peptide has healing and regeneration powers. It also helps in the preventing formation of gastric ulcers. This peptide is of great interest to researchers due to its numerous positive effects and benefits. DOSING LEVELS OF BPC-157: Not much about the dosing levels of BPC-157 has been researched yet but always try to concern the relevant persons before taking the medicine. The dosage of BPC-157 depends on the health and body conditions of the person taking it along with other related factors.

The National Pharmacy Association (NPA)'s Health Education Foundation (HEF) has funded a major study that aimed to test the SPUR tool and evaluate how effective it was at measuring medicines adherence. The study has been published in the British Medical Journal Open. Dr Joshua Wells, a fourth year PhD candidate at Kingston University, who was awarded the NPA bursary, was the lead researcher for the SPUR UK study, under the guidance of Professor Reem Kayyali. Created by Observia, a health research group, SPUR is a self-assessment questionnaire which helps to detect a patient's risk of medicine non-adherence and aims to accurately articulate the reasons for health behaviour. As well as funding from HEF, the study was made possible via a partnership with Kingston University and Kingston Hospital. HEF chair of Trustees, Dr Ian Cubbin, said: "We are delighted that NPA's Health Education Foundation has played a part in such an important study. This research could lead ultimately to a far more personalised, tailored approach to medicines optimisation - recognising that people's medicines behaviour can be highly individual to them."